# A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients

> **NCT05050604** · PHASE4 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 418 (estimated)

## Conditions studied

- Vascular Cognitive Impairment

## Interventions

- **DRUG:** Choline Alfoscerate 400mg
- **DRUG:** Placebo of Choline Alfoscerate 400mg

## Key facts

- **NCT ID:** NCT05050604
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09
- **Primary completion:** 2024-11
- **Final completion:** 2024-11
- **Target enrollment:** 418 (ESTIMATED)
- **Last updated:** 2021-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05050604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05050604, "A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05050604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*